You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Quick facts about treatment with VYXEOS for sAML

Learn key facts, statistics, and benefits of treatment with VYXEOS (vix-e-ose).


Induction and consolidation with VYXEOS

In a clinical trial including older adult patients with t-AML or AML-MRC in which patients received either VYXEOS or the standard AML chemotherapy treatment

icon icon

Approximately half of the patients treated with VYXEOS were alive at 9.6 months compared to 5.9 months for those treated with standard chemotherapy.a

icon icon

VYXEOS estimated survival at 1 year for patients was 42% compared to 28% for patients with standard chemotherapy.a

Downloadable quick facts about treatment with VYXEOS

Want a printable copy of the information above to share or keep for your reference?

Download now


VYXEOS is an intravenous (IV) chemotherapy used for the treatment of certain types of newly-diagnosed acute myeloid leukemia (AML) in adults and pediatric patients 1 year and older, including patients whose AML is related to previously received chemotherapy or radiation therapy (also called therapy-related AML, t-AML) and AML in patients who previously had certain types of blood disorders (also called AML with myelodysplasia-related changes, AML-MRC).


Important Safety Information

VYXEOS has different dosage recommendations from other medications that contain daunorubicin and/or cytarabine. Do not substitute VYXEOS for other daunorubicin and/or cytarabine-containing products.